arrow
T

Tim H. Brümmendorf

RWTH Aachen University
H指数:61
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

吉列替尼与异基因造血干细胞移植序贯治疗复发/难治FMS样酪氨酸激酶3(FLT3)突变急性髓系白血病患者的多中心真实世界研究

2026-09-050
OAAI
Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial

艾曲波帕联合环孢素A治疗中度再生障碍性贫血(EMAA):一项安慰剂对照、双盲、III期临床试验

Blood
IF23.1
2026-08-200
OAAI
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

慢性髓性白血病患者治疗中断缓解和分子学复发的全面分子特征分析:EURO-SKI生物标志物研究

Leukemia
IF13.4
2026-06-180
OAAI
Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms

年轻型和家族性骨髓增殖性肿瘤中频繁出现且具有临床意义的生殖系DNA修复基因变异

2026-01-050
OAAI
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms

NLRP3诱导的全身性炎症控制JAK2V617F突变性骨髓增殖性肿瘤的发生发展

2025-11-260
OAAI
Allogeneic stem cell transplantation from variant-carrying family donors leads to long-term engraftment in Telomere Biology Disorders

携带变异的家系供者异基因干细胞移植可导致端粒生物学疾病患者的长期植入

2025-08-250
OAAI
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment

CPX-351在急性髓系白血病中的诱导化疗:重新评估早期骨髓评估的作用

Leukemia
IF13.4
2025-07-030
OAAI
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry

骨髓增殖性肿瘤患者中应用抗血栓和细胞减少疗法减轻心房颤动相关并发症:来自GSG-MPN生物登记研究的启示

2025-03-170
OAAI
Telomere Length Is Associated With Adverse Atrial Remodeling in Patients With Atrial Fibrillation
2025-02-040
OAAI
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (vol 149, pg 913, 2022)

德国卓越中心在COVID-19大流行第一年中的癌症护理(vol 149, pg 913, 2022)

2025-01-180
OA
The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Asciminib与ATP竞争性酪氨酸激酶抑制剂的联合应用可能克服ASXL1突变对初诊CML患者分子反应的负面影响。

BLOOD
IF23.1
2024-11-051
PRE
CSF3RT6181 Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)

CSF3RT6181被Calnexin稳定,并诱导未折叠蛋白反应(UPR)和ER-Phagy:一种慢性中性粒细胞白血病(CNL)中致癌性错误折叠CSF3R蛋白的促生存通路。

BLOOD
IF23.1
2024-11-050
PRE
Author Correction: Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 (Vol 22, 288, 2016)

作者更正: Rps14单倍不足导致S100A8和S100A9介导的类红细胞分化阻滞 (第22卷,288,2016)

2024-10-230
OA
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy

可溶性及外泌体结合的CD27在实体瘤接受免疫治疗的患者中作为拮抗性生物标志物发挥作用。

2024-09-010
PRE
Effectiveness of a comprehensive support program for families with parental cancer (Family-SCOUT): results of a multicenter non-randomized controlled trial

父母癌症家庭综合支持计划的有效性 (Family-scoout): 一项多中心非随机对照试验的结果

2024-06-015
OAAI
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
2024-04-241
OAAI